China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment in a Phase I clinical study for its tetravalent influenza virus split vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against influenza, particularly for individuals aged three years and above.
Clinical Study Design and Objectives
The single-center, open-label study is designed to assess the safety and preliminary immunogenicity of the product in healthy subjects aged three years and above. This trial aims to evaluate the vaccine’s potential to stimulate the body’s immune response against the influenza virus, thereby preventing influenza caused by vaccine-related types of the virus.
Vaccine Market and Competition
Tetravalent influenza virus split vaccines are applicable to people aged three years and over, and can stimulate the body to produce immunity against the influenza virus. Several companies are already marketing their own versions of the vaccine in China, including Hualan Bio, GDK Bio, Changchun Institute of Biological Products, Sinovac, the Wuhan Institute of Biological Products, and the Shanghai Institute of Biological Products. Kangtai Biological’s entry into this market segment highlights the growing demand for effective influenza vaccines and the company’s commitment to contributing to public health through innovation.-Fineline Info & Tech
